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Abstract
Introduction: Women with triple-negative breast cancer have the worst prognosis, frequently present with
metastatic tumors and have few targeted therapy options. Notch-1 and Notch-4 are potent breast oncogenes that
are overexpressed in triple-negative and other subtypes of breast cancer. PEA3, an ETS transcription factor, is also
overexpressed in triple-negative and other breast cancer subtypes. We investigated whether PEA3 could be the
critical transcriptional activator of Notch receptors in MDA-MB-231 and other breast cancer cells.
Methods: Real-time PCR and Western blot analysis were performed to detect Notch-1, Notch-2, Notch-3 and Notch-
4 receptor expression in breast cancer cells when PEA3 was knocked down by siRNA. Chromatin
immunoprecipitation was performed to identify promoter regions for Notch genes that recruited PEA3. TAM-67 and
c-Jun siRNA were used to identify that c-Jun was necessary for PEA3 enrichment on the Notch-4 promoter. A
Notch-4 luciferase reporter was used to confirm that endogenous PEA3 or AP-1 activated the Notch-4 promoter
region. Cell cycle analysis, trypan blue exclusion, annexin V flow cytometry, colony formation assay and an in vivo
xenograft study were performed to determine the biological significance of targeting PEA3 via siRNA, Notch
signaling via a g-secretase inhibitor, or both.
Results: Herein we provide new evidence for transcriptional regulation of Notch by PEA3 in breast cancer. PEA3
activates Notch-1 transcription in MCF-7, MDA-MB-231 and SKBr3 breast cancer cells. PEA3 activates Notch-4
transcription in MDA-MB-231 cells where PEA3 levels are endogenously high. In SKBr3 and BT474 breast cancer
cells where PEA3 levels are low, overexpression of PEA3 increases Notch-4 transcripts. Chromatin
immunoprecipitation confirmed the enrichment of PEA3 on Notch-1 and Notch-4 promoters in MDA-MB-231 cells.
PEA3 recruitment to Notch-1 was AP-1-independent, whereas PEA3 recruitment to Notch-4 was c-JUN-dependent.
Importantly, the combined inhibition of Notch signaling via a g-secretase inhibitor (MRK-003 GSI) and knockdown
of PEA3 arrested growth in the G1 phase, decreased both anchorage-dependent and anchorage-independent
growth and significantly increased apoptotic cells in vitro. Moreover, either PEA3 knockdown or MRK-003 GSI
treatment significantly reduced tumor growth of MDA-MB-231 xenografts in vivo.
Conclusions: Taken together, the results from this study demonstrate for the first time that Notch-1 and Notch-4
are novel transcriptional targets of PEA3 in breast cancer cells. Targeting of PEA3 and/or Notch pathways might
provide a new therapeutic strategy for triple-negative and possibly other breast cancer subtypes.
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Breast cancer continues to be the second leading cause of
cancer-related deaths among women worldwide.
Approximately 70% of breast cancers are estrogen recep-
tor a-positive (ERa
+) and progesterone receptor-positive
(PR
+). They are divided into two subtypes: luminal A,
comprising those that are negative for the overexpression
or gene amplification of ErbB-2/HER2 and have low
levels of genes responsible for proliferation, and luminal
B, comprising those that are positive for HER2 and have
high expression of proliferation-associated genes [1,2].
This division is in part due to their sensitivity to antihor-
monal therapy such as tamoxifen or an aromatase inhibi-
tor. The luminal A subtype carries the best prognosis,
followed by luminal B. The third subtype is ER
-/PR
- and
HER2
+, which contains gene amplification for the ErbB-
2/HER2 oncogene. The HER2
+ subtype represents 15%
to 25% of breast cancers and is currently treated with
trastuzumab plus a taxane-based chemotherapy. The
HER2
+ subtype of breast cancer is associated with excel-
lent survival outcomes due to adjuvant trastuzumab ther-
apy, a humanized monoclonal antibody that targets the
HER2 receptor [3]. However, 30% to 60% of metastatic
HER2
+ breast cancer are resistant to trastuzumab. The
fourth subtype of breast cancer is the normal-like sub-
type, which resembles normal mammary epithelial cells
expressing genes associated with adipose tissue. The fifth
subtype represents 15% of breast cancers and is triple-
negative, and thus lacks expression of ER/PR and HER2.
Triple-negative breast cancers carry the worst prognosis
because of the lack of US Food and Drug Administra-
tion-approved targeted therapies [4,5]. Thus, there is an
immediate need for the elucidation of novel targets to
treat women with triple-negative breast cancer and to
increase these patients’ overall survival.
Notch signaling has emerged as a target for the treat-
ment of breast cancer [6]. In the mammalian system, there
are four Notch receptors (Notch-1, Notch-2, Notch-3 and
Notch-4) [7] and five known ligands (Delta-like 1, Delta-
like 3 and Delta-like 4 and Jagged-1 and Jagged-2) [8-10].
Cell-to-cell contact is critical for the activation of Notch
signaling, which subsequently enables the pathway to
modulate genes involved in cell fate such as proliferation
or differentiation [11]. Notch is processed in the trans-
Golgi apparatus, where it undergoes the first of three pro-
teolytic cleavages. The single polypeptide is cleaved (S1)
by furin-like convertase forming the mature Notch recep-
tor, which is a heterodimer consisting of Notch extracellu-
lar (NEC) and Notch transmembrane (NTM). The
receptor is trafficked to the plasma membrane, where it
awaits engagement with its membrane-associated ligand.
Upon ligand-receptor engagement, the second cleavage
(S2) by a disintegrin and metalloproteases 10 and 17
(ADAM10 and ADAM17, respectively) [12] releases NEC
to be endocytosed into the ligand-expressing cell. Sub-
sequently, NTM is cleaved (S3) by the g-secretase com-
plex, liberating the intracellular portion of Notch (NIC)
[13]. NIC translocates to the nucleus and binds to CBF-1,
a constitutive transcriptional repressor, displacing core-
pressors and recruiting coactivators such as Mastermind
[14,15]. Notch activates many genes associated with differ-
entiation and/or survival, including, but not limited to, the
HES and HEY family of basic helix-loop-helix transcrip-
tion factors [16], cyclin D1 [17] and c-Myc [18]. The third
and final cleavage step is critical for active Notch signaling.
Its inhibition can be exploited through emerging pharma-
cological drugs identified as g-secretase inhibitors (GSIs),
which attenuate signaling from all four receptors. Recent
studies have demonstrated that GSI treatment suppresses
breast tumor growth in a variety of breast cancer subtypes
[19-23], providing evidence of novel therapeutic
approaches.
The first evidence that Notch receptors are breast onco-
genes was provided by mouse studies. Overexpression of
constitutive, active forms of Notch-1 (N1IC) or Notch-4
(N4IC) form spontaneous murine mammary tumors in
vivo [11]. Furthermore, elevated expression of Notch-1
and/or its ligand Jagged-1 in human breast tumors is asso-
ciated with the poorest overall patient survival [24-26].
Recently, Notch-4 has been shown to be critical for the
survival of tumor-initiating cells [27]. Similarly to studies
performed using Notch-1, mouse mammary tumor virus
(MMTV)-driven Notch-3 receptor intracellular domain
expression in transgenic mice showed enhanced mammary
tumorigenesis [28]. In HER2
- breast cancers, downregula-
tion of Notch-3 resulted in suppressed proliferation and
increased apoptosis [29]. In contrast, overexpression of
Notch-2 in MDA-MB-231 cells significantly decreased
tumor growth and increased apo p t o s i si nv i v o[ 3 0 ] ,s u g -
gesting that Notch-2 is a breast tumor suppressor.
The factors that regulate Notch receptor expression in
breast cancer cells are still widely unknown. It has been
shown that p53 binds to the Notch-1 promoter and acti-
vates Notch-1 receptor transcription in human keratino-
cytes [31]. Activator protein 1 (AP-1) has been
demonstrated to be a transcriptional activator of Notch-
4 in human vascular endothelial cells [32]. We asked
which factors regulate Notch receptor transcription in
breast cancer.
Polyomavirus enhancer activator 3 (PEA3/E1AF/
ETV4) is a member of the ETS family of transcription
factors, which also includes ERM and ER-81. PEA3 is
overexpressed in metastatic breast carcinomas, particu-
larly triple-negative breast tumors [33]. PEA3 regulates
critical genes involved in inflammation and invasion,
such as IL-8 [34], cyclooxygenase-2 (COX-2) [35] and
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negative form of PEA3 reduced tumor onset and growth
in a MMTV/neu-transgenic model of breast cancer in
vivo [40]. PEA3 contains an ETS winged helix-turn-helix
DNA binding motif [41] that binds to the canonical
sequence GGAA/T on target genes [42]. The affinity of
binding relies on proximal sequences surrounding the
ETS binding site which aid in transcriptional control
based on context [43]. Phosphorylation of serine and
threonine residues by the mitogen-activating protein
kinase cascade activates PEA3 and is negatively regu-
lated by the ubiquitin-proteasome pathway as well as by
sumoylation [44-46].
The transcriptional activity of PEA3 is dependent on
other activators to regulate gene transcription and is
commonly partnered with AP-1 to regulate genes such
as MMP-1, MMP-3, MMP-7 and MMP-9 [36]; uroki-
nase-type plasminogen activator (uPA) [47]; COX-2
[35]; and ErbB-2 [48]. AP-1 is a dimeric complex con-
sisting of the Fos (c-FOS, FosB, Fra-1 and Fra-2) and
Jun (c-JUN, JunB and JunD) families [49]. Depending on
the cellular context, AP-1 cooperates with other proteins
including, but not limited to, NFB, CBP/p300, Rb and
PEA3 [50,51]. The functional role of AP-1 is to recruit
and direct appropriate factors to regulate gene expres-
sion and promote proliferation, differentiation, inflam-
mation and/or apoptosis [52].
Previous investigations have determined that overex-
pression of Notch-1 and Notch-4 plays a critical role in
breast tumorigenesis [11] and that PEA3 overexpression
is associated with aggressive breast cancers, particularly
the triple-negative subtype [53-58]. Herein we provide
novel evidence of a link between two pathways that are
overexpressed in breast cancer. PEA3 is a transcriptional
activator of Notch-1 and Notch-4 and a repressor of
Notch-2 in MDA-MB-231 cells, an example of triple-
negative breast cancer cells. PEA3-mediated Notch-1
transcription is AP-1-independent, while Notch-4 tran-
scription requires both PEA3 and c-JUN. PEA3 and/or
Notch signaling are essential for proliferation, survival
and tumor growth of MDA-MB-231 cells. Furthermore,
PEA3 is a transcriptional activator of both Notch-1 and
Notch-4 in other breast cancer cells. Thus we hypothe-
sized that targeting of the PEA3 and/or Notch pathways
might provide a new therapeutic strategy for triple-nega-
tive breast cancer as well as possibly other breast cancer
subtypes where PEA3 regulates Notch-1 and/or Notch-
4.
Materials and methods
Cell culture and reagents
MDA-MB-231, SKBr3, BT474 and MCF-7 breast cancer
cells were purchased from the American Type Culture
Collection (Manassas, VA, USA). All cell lines were
supplemented with 100 μm o ln o n e s s e n t i a la m i n oa c i d s
and 1% L-glutamine. SKBr3 cells (supplemented with
10% fetal bovine serum (FBS)) and MDA-MB-231 cells
(supplemented with 5% FBS) were maintained in
Iscove’s Minimal Essential Medium (IMEM). MCF-7
cells (supplemented with 10% FBS) were maintained in
DMEM/Ham’s Nutrient Mixture F-12. BT474 cells (sup-
plemented with 10% FBS) were maintained in DMEM.
All cells were cultured in a 37°C incubator with 5%
CO2. MRK-003 GSI was kindly provided by Merck
Oncology International, Inc. (33 Avenue Louis Pasteur,
Boston, MA, USA). MRK-003 GSI was dissolved in
dimethylsulfoxide (DMSO) and stored at -80°C until
use. Lactacystin (L6785) was purchased from Sigma-
Aldrich (St Louis, MO, USA), dissolved in deionized
water and stored at -20°C until use. The pcDNA3.1
expression vector and the PEA3-pcDNA3.1 expression
vector were kindly provided by Dr Mein-Chie Hung
(The University of Texas MD Anderson Cancer Center,
Houston, TX, USA). The pHMB empty and pHMB-
TAM-67 expression vectors were kindly provided by Dr
Richard Schultz, Department of Immunology and
Microbiology, (Loyola University Medical Center, May-
wood, IL, USA).
RNA interference and reagents
Control scrambled siRNA-a (sc-37007), Notch-1 siRNA
(sc-36095), and a smart pool of three distinct PEA3
siRNA (PEA3ia, sc-36205) were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). An unre-
lated control siRNA and PEA3 siRNA (PEA3ib, catalog
number 115237) were purchased from Ambion (Austin,
TX, USA). A smart pool of four distinct c-Jun siRNA
(sc-29223) were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA). Transfection reagents used
were Lipofectamine 2000 and Lipofectamine RNAiMAX,
which were purchased from Invitrogen (Carlsbad, CA,
USA), and FuGENE 6 was purchased from Roche Diag-
nostics Corporation (Indianapolis, IN, USA). Protocols
were performed as described by the manufacturers.
Antibodies
Notch-1 (antibody clone C-20), Notch-4 (antibody clone
H-225), PEA3 [16] (product number sc-113), c-JUN
(antibody clone G-4) were purchased from Santa Cruz
Biotechnology. b-actin (antibody clone AC-15) was pur-
chased from Sigma-Aldrich and used as the loading
control
Real-time RT-PCR
Total RNA was extracted from the cells using the
RNeasy Mini Kit (Qiagen, Valencia, CA, USA) according
to the manufacturer’s protocol. Total cDNA was
reverse-transcribed from the total RNA with random
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Kit (Applied Biosystems, Foster City, CA, USA) accord-
ing to the manufacturer’s protocol. Analysis of transcript
relative fold copy number adjusted to hypoxanthine-
guanine phosphoribosyl transferase (HPRT), an endo-
genous control, was carried out by quantitative real-time
PCR using iTaq™ SYBR Green Supermix with ROX
(Bio-Rad Laboratories, Hercules, CA, USA) and the Plu-
sOne thermal cycler from Applied Biosystems. The fol-
lowing primers were used for detection: Notch-1
(forward primer: 5’-GTCAACGCCGTAGATGACC-3’,
reverse primer: 5’-TTGTTAGCCCCGTTCTTCAG-3’),
Notch-2 (forward primer: 5’-TCCACTTCATACTCA-
CAGTTGA-3’, reverse primer: 5’-TGGTTCAGAGAA
AACATACA-3’), Notch-3 (forward primer: 5’-GGGAA
AAAGGCAATAGGC-3’,r e v e r s ep r i m e r :5 ’-GGAGG-
GAGAAGCCAAGTC-3’), Notch-4 (forward primer:
5’-AACTCCTCCCCAGGAATCTG-3’,r e v e r s ep r i m e r :
5’-CCTCCATCCAGCAGAGGTT-3’), PEA3 (forward
primer: 5’-AGGAGACGTGGCTCGCTGA-3’), (reverse
primer: 5’-GGGGCTGTGGAAAGCTAGGTT-3’), HEY-
1 (forward primer: 5’-TGGATCACCTGAAAATGCTG-
3’, reverse primer: 5’-TTGTTGAGATGCGAAACCAG-
3’), MMP-9 (forward primer: 5’-TCGTGGTTCCA
ACTCGGTTT-3’, reverse primer: 5’-GCGGCCCT
CGAAGATGA-3’)a n dI L - 8( f o r w a r dp r i m e r :5 ’-
CACCGGAAGGAACCATCTCACT-3’, reverse primer:
5’-TCAGCCCTCTTCAAAAACTTCTCC-3’), with
HPRT (forward primer: 5’-ATGAACCAGGTTAT-
GACCTTGAT-3’, reverse primer: 5’-CCTGTTGACTGG
TCATTACAATA-3’) used as the loading control. Proto-
cols were performed as described by the manufacturers.
Transfection conditions for Western blot analysis and
RT-PCR were as follows. MDA-MB-231 (4 × 10
5),
M C F - 7( 4×1 0
5) ,S K B r 3( 5×1 0
5)a n dB T 4 7 4( 5×1 0
5)
cells were placed into a six-well culture dish. Twenty-
four hours later the cells were transfected with reagents.
Forty-eight hours later cells were harvested and protein/
RNA was extracted. Notch-4 luciferase constructs were
generously provided by Dr Emery Bresnick, Cell &
Regenerative Biology, (University of Wisconsin at Madi-
son, Madison, WI, USA). The AP-1 luciferase construct
was generously provided by Dr Richard Schultz, Depart-
ment of Immunology and Microbiology,(Loyola Univer-
sity Medical Center, Maywood, IL, USA). Dual-luciferase
assays were performed as described by the manufacturer
(Promega, Madison, WI, USA). A pRL-thymidine kinase
promoter-driven Renilla luciferase reporter was cotrans-
fected with the Firefly luciferase construct mentioned
above as an internal transfection control. Transfection
activity was measured using the Veritas Microplate
Luminometer (Turner Biosystems, Sunnyvale, CA, USA)
and represented as the ratio of Firefly luciferase to
Renilla luciferase.
Western blot analysis
The cells were lysed in radioimmunoprecipitation assay
buffer (pH 8.0) containing 50 mmol Tris HCl, 150 mmol
NaCl, 1% Nonidet P-40 (NP-40), 0.5% sodium deoxycho-
late, 0.1% SDS, 25 mmol b-glycerophosphate, 1 mmol
sodium orthovanadate, 1 mmol sodium fluoride, 1 mmol
phenylmethylsulfonyl fluoride, 1 mg/mL aprotinin and
1 mg/mL leupeptin. Western blot analysis was performed
as previously described [21]. NuPAGE Bis-Tris Gels (4%
to 12%; Invitrogen) in 3-(N-morpholino)propanesulfonic
acid buffer were run at 175 V for 1.5 hours, and proteins
were transferred at 38 V for 2 hours using polyvinylidene
fluoride membranes. Protein detection was performed
using the SuperSignal West Dura Substrate (Thermo
Scientific, Rockford, IL, USA) and visualized by using the
FUJIFILM™ Las-300 imager (GE-Healthcare Bio-Sciences,
Piscataway, NJ, USA).
Chromatin immunoprecipitation
MDA-MB-231 cells (3 × 10
6)w e r ep l a t e di n1 5 0 - c m
2
Petri dishes. Twenty-four hours later cells were trans-
fected with pcDNA3.1, PEA3-pcDNA3.1 and PEA3-
pcDNA3.1, together with PEA3 siRNA, for 48 hours. The
cells were cross-linked with 1% formaldehyde and lysed
in SDS lysis buffer (1% SDS, 10 mmol ethylenediaminete-
traacetic acid (EDTA), 50 mmol Tris HCl, pH 8.1). The
lysates were sonicated using the Branson Sonifier model
250 (Branson Ultrasound Corp., Danbury, CT, USA) at
output 4.5, duty cycle 50, and pulsed 10 times. The lysate
was then diluted 1:10 in immunoprecipitation dilution
buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mmol EDTA,
16.7 mmol Tris HCl, 167 mmol NaCl, pH 8.1). Approxi-
mately 300 to 700 μg of total precleared protein in lysates
were incubated with 4 μg of PEA3 antibody (sc-113X;
Santa Cruz Biotechnology) or mouse immunoglobulin G
(IgG) overnight. Fifty microliters of protein G-plus agar-
ose beads (sc-2002; Santa Cruz Biotechnology) were
added to the immune complexes for 2 hours while gently
rocking. Immune complexes/beads were washed in low-
salt buffer (0.1% SDS, 1% Triton X-100, 2 mmol EDTA,
20 mmol Tris HCl, 150 mmol NaCl, pH 8.1), high-salt
buffer (0.1% SDS, 1% Triton X-100, 2 mmol EDTA,
20 mmol Tris HCl, 500 mmol NaCl, pH 8.1), LiCl buffer
(1% sodium deoxycholate, 1% NP-40, 0.25 mol LiCl,
1 mmol EDTA, 10 mmol Tris HCl, pH 8.1) and Tris-
EDTA buffer (1 mmol EDTA and 10 mmol Tris HCl) at
4°C with agitation. The protein/antibody complexes from
beads were eluted in freshly prepared elution buffer (1%
SDS, 0.1 mol sodium bicarbonate, pH 8.0). Cross-linking
of proteins and DNA was reversed by heating at 65°C
overnight while gently rocking. The protein was degraded
using a proteinase solution (0.5 mol EDTA, 1 M Tris
HCl, pH 8.0, 10 mg/mL proteinase K) and incubated at
52°C for 1 hour. DNA was isolated using the QIAquick
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sites was detected by quantitative PCR using iTaq™
SYBR Green Supermix with ROX (Bio-Rad Laboratories).
Ct threshold values were normalized to the IgG control.
The following promoter region primers were used in
detection: Notch-1 promoter regions not containing ETS
or AP-1 sequences served as negative controls (forward
primer: 5’-GTGCACACGGCTGTCCG-3’,r e v e r s ep r i -
mer: 5’-GCGACAACTGGCGACTGAA-3’), 2× PEA3
(forward primer: 5’-GCTGCAAGAGCCAAGATGAA-3’,
reverse primer: 5’-GGTGCCTGTGTTGAAAGCTCT-3’),
c-ETS (forward primer: 5’-CTCCTGGCGCTTAAC-
CAGG-3’, reverse primer: 5’-CCAGAAAGCACAAACG
GGTC-3’), AP-1(A) (forward primer: 5’-GCCTCCTT
AGCTCACCCTGA-3’), reverse primer (5’-TCTTCA-
GAGGCCCCCTGC-3’), AP-1(B) (forward primer: 5’-TC
CGCAAACCAGGCTCTG-3’, reverse primer: 5’-ATTGG
GGTGCAGTGCCG-3’), Sp-1/PEA3 (forward primer: 5’-
CACCTCGACTCTGAGCCTCAC-3’, reverse primer: 5’-
CTCTTCCCCGGCTGGCT-3’). Notch-4 promoter
regions not containing ETS or AP-1 sequences served as
negative controls (forward primer: 5’-GGCGAGGATTC-
TAATGTGGA-3’, reverse primer: 5’-CCCTGA GTGAA
AGGGTGAAG-3’), CBF-1 (forward primer: 5’-TGGTA
CCACCCTGGTCAGTAT-3’, reverse primer: 5’-TGCT
CAGGCATTATGAGCTATG-3’), AP-1(A) (forward pri-
mer: 5’-AGCTGCCACTGACACCTTCT-3’, reverse pri-
mer: 5’-CAGGGAATGCCAGTCAGAAT-3’), AP-1(B)
(forward primer: 5’-ACTTCCCCAGGGG TTGTC-3’,
reverse primer: 5’-CTTCCTCCTCGGC CTGCT-3’)a n d
PEA3/ETS (forward primer: 5’-GGGTTCCTCTTC
CCCATACC-3’, reverse primer: 5’-TCATTT TCCCAT-
CACCTTCCTT-3’).
Coimmunoprecipitation
MDA-MB-231 cells (3 × 10
6) were plated in 150-cm
2 Petri
dishes for 24 hours. The cells were transfected with
pcDNA3.1, PEA3-pcDNA3.1 and PEA3-pcDNA3.1,
together with PEA3 siRNA, for 48 hours. The cells were
cross-linked with 1% formaldehyde and lysed in SDS lysis
buffer (1% SDS, 10 mmol EDTA, 50 mmol Tris HCl, pH
8.1). The lysates were sonicated using the Branson Sonifier
250 at output 4.5, duty cycle 50, and pulsed 10 times. The
lysate concentration was ascertained and was equally
diluted in immunoprecipitation dilution buffer (0.01%
SDS, 1.1% Triton X-100, 1.2 mmol EDTA, 16.7 mmol Tris
HCl, 167 mmol NaCl, pH 8.1). Approximately 300 to
700 μg of total precleared lysates were incubated with 3 μg
of PEA3 antibody (sc-113X; Santa Cruz Biotechnology) or
mouse IgG overnight. Thirty microliters of protein G-plus
agarose beads (sc-2002, Santa Cruz Biotechnology) were
added to the immune complexes for 2 hours while gently
rocking. Immune complexes and beads were washed three
times in PBS. The pellet was resuspended in Laemmli
sample buffer with 5% b-mercaptoethanol (Bio-Rad
Laboratories) and heated for 5 minutes at 95°C while vig-
orously shaking. Western blot analysis was used to detect
coimmunoprecipitation proteins as described above. Anti-
bodies used for detection were PEA3 (16), c-FOS (H-125),
c-JUN (G-4) and Fra-1 (R-20).
Cell cycle analysis
MDA-MB-231 cells (1 × 10
5) were seeded into a six-well
plate. After 24 hours, the cells were treated/transfected
with DMSO/scrambled, control siRNA, DMSO/PEA3
siRNA, MRK-003 (10 μmol)/scrambled siRNA or MRK-
003 (10 μmol)/PEA3 siRNA. Briefly, 24 and 48 hours
posttreatment/posttransfection, the cells and media were
isolated and permeabilized with 70% ethanol. The cells
were then pelleted, washed in 5% bovine calf serum and
resuspended in 10 μg/mL RNase/PBS solution. The cells
were stained with propidium iodide (100 μg/mL) and
analyzed by flow cytometry (FACSCanto; BD Biosciences,
San Jose, CA, USA).
Annexin V
MDA-MB-231 cells (1.5 × 10
5) were seeded into a six-well
plate for 24 hours. Cells were treated/transfected with
DMSO/scrambled siRNA, DMSO/PEA3 siRNA, MRK-003
(10 μmol)/scrambled siRNA and MRK-003 (10 μmol)/
PEA3 siRNA. Briefly, after 24 and 48 hours of treatment/
transfection, 1 × 10
6 cells were isolated in 1× annexin
binding buffer (0.1 mol 4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid/NaOH, 140 mol NaCl, 25 mmol
CaCl2, pH 7.4) and treated with both fluorescein isothio-
cyanate-annexin V stain and propidium iodide. After 1-
hour incubation, the samples were subjected to analysis by
flow cytometry (FACSCanto; BD Biosciences).
Cell viability assay
MDA-MB-231 cells (1.5 × 10
5) were seeded into a six-
well plate for 24 hours. Cells were treated/transfected
with DMSO/scrambled siRNA, DMSO/PEA3 siRNA,
MRK-003 (10 μmol)/scrambled siRNA and MRK-003
(10 μmol)/PEA3 siRNA. Briefly, after 24 and 48 hours of
treatment/transfection, cells and media were harvested
and washed in PBS. The cells were stained with trypan
blue and counted under a standard slide microscope at
×40 magnification.
Colony formation assay
In a six-well plate, a bottom layer of 1 mL of 0.8% agar dis-
solved in IMEM was added. Two milliliters of a 2% methyl-
cellulose/IMEM solution (supplemented with 5% FBS, 1%
nonessential amino acids and 1% L-glutamine) were added
on top of the agar. MDA-MB-231 cells (1 × 10
3 cells/mL)
were treated/transfected with DMSO/scrambled siRNA,
DMSO/PEA3 siRNA, MRK-003 (5 μmol)/scrambled
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Treated cells were added directly to the methylcellulose
solution. The assay was left untouched for 14 days at 37°C
and 5% CO2. Colonies were stained with crystal violet for
1 hour, photographed and counted under a standard light
microscope at ×40 magnification. Nine fields per well were
counted.
MDA-MB-231 xenograft study
MDA-MB-231 cells were transfected in vitro with control
or PEA3 siRNA smart pool for 24 hours as described pre-
viously. One million cells were subsequently injected into
each of two mammary fat pads of 10 Balb/c athymic
nude mice per group, for a total of 40 mice. The mice
were randomized to control siRNA or PEA3 siRNA and
fed orally by gavage, vehicle control (2% carboxymethyl-
cellulose in sterile PBS) or 100 mg/kg MRK-003 GSI for
three consecutive days per week. The tumor areas were
measured using vernier calipers, and growth rates were
calculated by linear regression analysis. The tumor areas
were monitored biweekly for up to 3.5 weeks. The proto-
cols used to study breast tumor xenografts in mice were
approved by Loyola University’s Institutional Animal
Care and Use Committee.
Results
PEA3 regulates Notch-1, Notch-2 and Notch-4 receptor
transcripts
To investigate the role of PEA3 in Notch expression, we
examined the effect of two independent PEA3 RNA inter-
ference sequences on the expression of Notch-1 through
Notch-4 receptor mRNA as measured by real-time PCR.
Notch-1 and Notch-4 transcripts were decreased by nearly
50% and 70%, respectively, upon PEA3 knockdown by
either PEA3ia or PEA3ib siRNA. Notch-3 transcript levels
remained unchanged. Interestingly, Notch-2 levels showed
a moderate but significant increase upon PEA3 knock-
down, which, upon further investigation, may prove to be
advantageous, since it has been correlated with proapopto-
tic and breast tumor suppressive function [30] (Figure 1A,
lower left graphs). PEA3 transcripts were measured as a
control for the efficacy of PEA3 knockdown using the two
types of PEA3 siRNA (Figure 1A, upper left graph).
To determine whether the effect on Notch-1 and
Notch-4 transcripts correlated with protein expression,
protein lysates from cells transfected with either a
scrambled, control siRNA (SCRBia) or PEA3 siRNA
(PEA3ia) for 48 hours were subjected to Western blot
analysis. The results showed a reduction of Notch-1
full-length and transmembrane receptor protein levels
by 50% (Figure 1B, upper right panel). To visualize the
effects of PEA3 siRNAa on the rapidly turned over
Notch-4 receptor, we treated MDA-MB-231 cells with
or without lactacystin, a specific proteasome inhibitor,
for 24 hours before lysing cells for total proteins. Conse-
quently, N4IC protein levels were decreased by 90%
upon PEA3 knockdown (Figure 1B, upper right panel).
To confirm the effect of PEA3 siRNAa on the levels and
activity of PEA3, PEA3 and its classical downstream tar-
gets were measured by real-time PCR after transfection
w i t hc o n t r o lo rP E A 3s i R N Af o r4 8h o u r s .P E A 3t r a n -
scripts were significantly reduced (Figure 1A, left graph) as
well as its known target gene MMP-9 (Figure 1C). More-
over, HEY-1, a classic downstream target of the Notch sig-
naling pathway, was also significantly reduced upon PEA3
knockdown. Taken together, these results suggest that
PEA3 positively regulates Notch-1 and Notch-4 receptor
expression and affects Notch activity in MDA-MB-231
cells.
PEA3 regulates Notch-1 and Notch-4 expression in other
subtypes of breast cancer
Our investigations are the first to show that PEA3 is a
transcriptional activator of Notch-1 and Notch-4 in MDA-
MB-231 breast cancer cells, an example of triple-negative
breast cancer. We next assessed whether this is a common
mechanism among the other subtypes of breast cancer
cells. We used the single pool of PEA3 siRNAa because
similar results were obtained for the two independent
siRNA. MDA-MB-231 (triple-negative), MCF-7 (luminal
A), BT474 (luminal B) and SKBr3 (HER2
+) cells were
transfected with either scrambled or PEA3 siRNAa. Nor-
malized to MDA-MB-231 cells, MCF-7 cells had slightly
less PEA3 transcripts, followed by BT474 cells and then
SKBr3 cells (Figure 2A). Notch-1 (Figure 2B) and Notch-4
(Figure 2C) transcript levels were compared with either
scrambled or PEA3 siRNA among the cell lines. PEA3 reg-
ulation of Notch-1 was seen in MDA-MB-231, SKBr3 and
MCF-7 cells, but not BT474 cells (Figure 2B). However,
PEA3-mediated effects on Notch-4 transcripts were
observed only in MDA-MB-231 cells (Figure 2C). This
could be due in part to the fact that PEA3 basal transcript
levels were very low in other cell types (Figure 2A). Moti-
vated by this notion, we asked whether we could drive the
expression of Notch-4 by increasing levels of PEA3 in
breast cancer cells that express low endogenous PEA3
levels. To address this question, BT474 and SKBr3 cells
were transfected with either pcDNA3.1 vector alone or
PEA3-pcDNA3.1 expression plasmid. Notch-1 transcripts
remained unchanged when PEA3 was overexpressed (Fig-
ures 2D and 2E). Notch-4 transcript levels were signifi-
cantly increased ninefold in BT474 (Figure 2D) and
sixteenfold in SKBr3 breast cancer cells (Figure 2E).
Taken together, PEA3 is required for Notch-1 tran-
scription in at least three subtypes of breast cancer cells:
MDA-MB-231, SKBr3 and MCF-7. However, PEA3 is an
activator of Notch-4 transcription in MDA-MB-231 cells
where endogenous PEA3 levels are high. Exogenous
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Page 6 of 18expression of PEA3 in BT474 and SKBr3 cells provides
evidence that it is also a potential activator of Notch-4
transcription in other breast cancer subtypes.
PEA3 is enriched on the Notch-1 and Notch-4 promoters
To determine the mechanism by which PEA3 regulates
Notch-1 and Notch-4 transcription, we scanned the pro-
moter regions of Notch-1 and Notch-4 using the National
Center for Biotechnology Information Entrez GenBank
[59,60] and identified several ETS binding sites (Figures
3B and 3C, respectively). Interestingly, both promoters
contained two AP-1 sites adjacent to ETS sites. A classic
CBF-1 site was also previously identified in the Notch-4
promoter [23] and was used as a negative control for
PEA3 recruitment. Primers were subsequently designed
to include these identified regions. Primers flanking pro-
moter regions containing no known consensus sites were
used as negative controls. We then performed chromatin
immunoprecipitation (ChIP) experiments on lysates from
MDA-MB-231 cells that were transfected with either
pcDNA3.1 vector alone or pcDNA3.1-PEA3 expression
plasmid.
To confirm that PEA3 was overexpressed in MDA-
MB-231 cells, immunoprecipitation (IP) followed by
Western blot analysis was performed to detect PEA3
protein (Figure 3A). The IP followed by Western blot
analysis showed that endogenous PEA3 could not be
detected in pcDNA3.1-transfected MDA-MB-231 cells.
However, cells transfected with the PEA3 expression
plasmid expressed PEA3 protein (Figure 3A). The ChIP
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Figure 1 PEA3 positively regulates Notch-1 and Notch-4 transcription. MDA-MB-231 cells were transfected with one of two unrelated
scrambled siRNA (SCRBia or SCRBib) or one of two unrelated PEA3 siRNA (PEA3ia or PEA3b). (A) Relative mRNA levels of Notch receptors
(NOTCH-1, NOTCH-2, NOTCH-3 and NOTCH-4) were measured by quantitative PCR. Relative mRNA levels of PEA3 were measured as knocked-
down controls using quantitative PCR. (B) Protein levels of Notch-1 and Notch-4 were detected by Western blot analysis. For Notch-4 Western
blot analysis, cells were treated with or without lactacystin for 24 hours. The Western blots are representative of three independent experiments.
(C) Downstream targets of PEA3 (MMP-9) and Notch (HEY-1) were measured by quantitative PCR. Transcripts were normalized to HPRT, and
mean values were plotted. Error bars represent standard deviations. The statistical significance of three or more experiments was determined by
performing a two-tailed, unpaired Student’s t-test for two comparisons.
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Page 7 of 18analysis was performed on cells transfected with vector
alone or with PEA3 expression plasmid (Figures 3B and
3C). Endogenous PEA3 was not enriched in either the
Notch-1 or Notch-4 promoter regions in cells transfected
with pcDNA3.1. This could be due to weak antibody
avidity or, more likely, could be a result of PEA3 protein
instability [61]. PEA3 enrichment was found in both
Notch-1 and Notch-4 promoter regions within 1 kb of
the start site when PEA3 was overexpressed compared
to vector alone-transfected cells (Figures 3B and 3C). A
PEA3 siRNA smart pool was used to confirm the speci-
ficity of PEA3 recruitment and the PEA3 antibody. Fig-
ure 4A shows that PEA3 siRNA significantly decreased
the enrichment of PEA3 in the identified promoter
regions of Notch-1 and Notch-4 compared to a control
siRNA. The Western blot shown in Figure 4B confirms
that the overexpressed PEA3 in MDA-MB-231 cells was
almost completely knocked down using the PEA3 siR-
NAa smart pool.
To address whether PEA3 acts with AP-1 in Notch-1
and Notch-4 promoter regions, since it is known to
work in accordance with c-Jun on several other genes
[34,35,50], transfected lysates with either phMB-vector
or phMB-TAM-67, a dominant-negative form of c-Jun
missing the transactivation domain [62], were subjected
to ChIP analysis. PEA3 enrichment on the Notch-1 pro-
moter was not affected by TAM-67 (Figure 5A). How-
ever, PEA3 recruitment to an ETS site adjacent to an
AP-1 site approximately 70 nt upstream from the start
site of the Notch-4 promoter was significantly decreased
by expression of TAM-67 (Figure 5B), indicating that
the transactivation domain of c-Jun is required for
PEA3 recruitment to the Notch-4 promoter. To confirm
that TAM-67 reduces AP-1 transcriptional activity, an
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Figure 2 PEA3 regulates Notch-1 and Notch-4 in different subtypes of breast cancer. (A) through (C) MDA-MB-231, MCF-7, BT474 and
SKBr3 cells were transfected with either scrambled or PEA3 siRNAa. Once normalized to MDA-MB-231 cells, the transcript levels of PEA3 (A),
Notch-1 (A) and Notch-4 (C) were compared and measured by quantitative real-time PCR. BT474 cells (D) and SKBr3 cells (E) were transfected
with either empty vector or PEA3 expression plasmid. Notch-1 and Notch-4 mRNA levels were normalized to empty vector and measured by
quantitative PCR. Means and standard deviations of three experiments were plotted. Statistical significance was determined by performing a
two-tailed, unpaired Student’s t-test.
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Page 8 of 18AP-1 luciferase reporter assay was performed in MDA-
MB-231 cells transfected with either phMB vector alone
or phMB-TAM-67. The results showed that the TAM-
67-transfected cells contained more than 50% less AP-1
reporter activity than vector alone-transfected cells
(Figure 5). To determine whether c-Jun specifically is
required for PEA3 enrichment in the identified Notch-4
promoter region, transfected lysates with either control
or c-Jun siRNA smart pool were subjected to ChIP ana-
lysis. In agreement with our previous findings, PEA3
enrichment in the Notch-4 promoter region was signifi-
cantly decreased upon knockdown of c-Jun (Figure 5B),
suggesting that c-Jun is required for PEA3 enrichment
in the identified Notch-4 promoter region. We
c o n f i r m e dt h a tc - J u np r o t e i nw a sk n o c k e dd o w nb y
siRNA on the basis of Western blot analysis (Figure 5B).
We also confirmed that c-Jun protein was in a complex
with PEA3 in MDA-MB-231 nuclear extract by per-
forming a co-IP assay (Figure 5C).
To assess whether the results of the ChIP studies were
not due to artificial interactions as a result of PEA3 over-
expression, we performed a Notch-4 luciferase reporter
assay using a minimal promoter region (-650 to +1) which
contains the same AP-1/ETS region just -70 nt upstream
from the start site. The wild-type construct contained an
intact AP-1 and ETS consensus site at -70 nt. The mutant
AP-1 construct contained an ablated AP-1 consensus site,
but the adjacent ETS binding site was preserved [32].
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Figure 3 PEA3 is enriched on the Notch-1 and Notch-4 promoters. (A) MDA-MB-231 cells were transfected with pcDNA3.1 alone or
pcDNA3.1-PEA3 expression plasmid. Lysates were immunoprecipitated (I.P.) with IgG control or PEA3-specific antibody. Western blot analysis was
performed to detect PEA3. Heavy and light chains of IgG were used for loading. The Western blots are representative of three independent
experiments. (B) and (C) MDA-MB-231 cells transfected with pcDNA3.1 or pcDNA3.1-PEA3 expression plasmid were lysed, and lysates were
subjected to chromatin immunoprecipitation using either PEA3-specific antibody or an isotype control IgG on the Notch-1 promoter (B) or the
Notch-4 promoter (C), respectively. PEA3 enrichment was measured by quantitative PCR and normalized to pcDNA3.1 and IgG control.
Schematic representations of Notch-1 and Notch-4 promoter regions and the primers used in the studies flanking the specific sites are shown.
Error bars represent standard deviations. Statistical significance of three or more experiments was determined by performing a two-tailed,
unpaired Student’s t-test for two comparisons.
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Page 9 of 18Knockdown of endogenous PEA3 using siRNA signifi-
cantly decreased wild-type AP-1-containing reporter activ-
ity (Figure 6, right graph) or mutant AP-1-containing
reporter activity (Figure 6, inset) compared to the
scrambled control. These results suggest that both PEA3
andAP-1 are critical for the regulation of the -70 nt region
within the Notch-4 promoter in MBA-MD-231 cells. As a
control study, we observed no significant difference in AP-
1 luciferase reporter activity upon PEA3 knockdown, indi-
cating that PEA3 was not mediating effects on the Notch-4
promoter indirectly through AP-1 regulation (Figure 6, left
graph). Herein we provide the first evidence that both
PEA3 and c-Jun are required to activate the Notch-4
promoter.
Differential regulation of Notch-4 by AP-1 members
To determine which members of the Fos family of tran-
scription factors are required for Notch-4 transcription,
we performed real-time PCR to detect Notch-4 tran-
scripts in response to knockdown of Fra-1 and c-FOS,
which are the major forms of Fos in MDA-MB-231
cells. The results showed that Notch-4 transcripts were
decreased 2.5-fold when Fra-1 was knocked down simi-
larly to PEA3 or c-JUN knockdown (Figure 7A, upper
0.0
0.5
1.0
1.5
2.0
2.5
3.0
NOTCH-4
AP-1
*
Control siRNA
PEA3 siRNA
Control siRNA
PEA3 siRNA
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
NOTCH-1
c-ETS
*
R
e
l
a
t
i
v
e
 
F
o
l
d
 
I
n
d
u
c
t
i
o
n
(
s
p
e
c
i
f
i
c
 
P
E
A
3
 
A
b
/
 
I
g
G
)
R
e
l
a
t
i
v
e
 
F
o
l
d
 
I
n
d
u
c
t
i
o
n
(
s
p
e
c
i
f
i
c
 
P
E
A
3
 
A
b
/
 
I
g
G
)
p<0.001 p<0.001
pcDNA3.1
pcDNA3.1-PEA3
Control siRNA
PEA3 siRNA
PEA3
+       – –
– +       + 
– +       –
––+  
Actin
A.
B.
Figure 4 PEA3 is required for enrichment in Notch-1 and Notch-4 promoter regions. (A) MDA-MB-231 cells were cotransfected with
pcDNA3.1-PEA3 expression plasmid and control siRNAa or PEA3 siRNAa. Lysates were subjected to chromatin immunoprecipitation using either
PEA3-specific antibody or an isotype control IgG on the Notch-1 and Notch-4 promoters, respectively. PEA3 enrichment was measured by
quantitative PCR and normalized to IgG control. Statistical comparisons were performed between PEA3 siRNAa and control siRNAa using a two-
tailed, unpaired Student’s t-test for two comparisons. (B) Lysates from the experiment described in (A) were subjected to SDS-PAGE followed by
Western blot analyses to detect PEA3 protein and actin protein as a loading control. The Western blots are representative of three independent
experiments. Error bars represent standard deviations. The statistical significance of three or more experiments was determined by performing a
two-tailed, unpaired Student’s t-test for two comparisons.
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Page 10 of 18graph). Conversely, c-FOS siRNA increased Notch-4
transcripts twofold compared to a scrambled control
siRNA (Figure 7A, lower graph). Figure 7B demonstrates
the efficacy of knockdown by PEA3, c-Jun, Fra-1 and c-
FOS siRNA as measured by real-time PCR and Western
blot analysis. These results, together with those of the
previous ChIP studies, suggest that PEA3 regulates
Notch-4 transcription by potentially interacting with c-
Jun and Fra-1. The results also indicate that c-FOS is a
potential transcriptional repressor of Notch-4.
Dual inhibition of Notch and PEA3 inhibits cell
proliferation and induces apoptosis
Notch is vital for proliferation and cell fate determina-
tion [63], whereas PEA3 is critical for cell migration and
invasion [64,65]. Both aberrant and unregulated
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Figure 5 The requirement of c-JUN for PEA3 enrichment on the Notch-4 promoter. (A) MDA-MB-231 cells were cotransfected with
pcDNA3.1-PEA3 and phMB vector alone or with phMB-TAM-67 expression plasmid. Lysates were subjected to chromatin immunoprecipitation
using either PEA3-specific antibody or an isotype control IgG on the Notch-1 or Notch-4 promoter, respectively. PEA3 enrichment was measured
by quantitative PCR and normalized to IgG control. In an independent experiment, cells were cotransfected with an AP-1 luciferase reporter,
Renilla luciferase and phMB or phMB-TAM-67. Dual Firefly and Renilla luciferase assays were performed to measure AP-1 activity. Statistical
comparisons were performed between phMB-vector and phMB-TAM-67 using a two-tailed, unpaired Student’s t-test for two comparisons. (B)
MDA-MB-231 cells were cotransfected with pcDNA3.1-PEA3 expression plasmid and control siRNA or c-JUN siRNA. Lysates were subjected either
to chromatin immunoprecipitation and quantified as described above or to SDS-PAGE followed by Western blot analyses to detect c-JUN and
actin (loading control). Statistical comparisons were performed between control siRNA and c-JUN siRNA using a two-tailed, unpaired Student’s t-
test for two comparisons. (C) PEA3 was immunoprecipitated from MDA-MB-231 lysates exogenously expressing PEA3 followed by Western blot
analysis to detect PEA3 and c-JUN. The light chain of IgG was detected for loading purposes. The Western blots are representative of three
independent experiments. Error bars represent standard deviations. The statistical significance of three or more experiments was determined by
performing a two-tailed, unpaired Student’s t-test for two comparisons.
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Page 11 of 18activities can lead to overall malignancy and poor survi-
val [25,40]. To understand their biological significance
and their effect in MDA-MB-231 triple-negative cells,
we explored dual inhibition of PEA3 and Notch using
the specific PEA3 siRNA smart pool and the preclinical
MRK-003 GSI, respectively. MDA-MB-231 cells were
transfected with scrambled control or PEA3 siRNA
alone, treated with vehicle or MRK-003 GSI, or a com-
bination of PEA3 siRNA plus MRK-003 GSI thereof for
48 hours. Independently, PEA3 knockdown or Notch
inhibition had little effect on the cell cycle compared to
control (Figure 8A). PEA3 knockdown or MRK-003 GSI
treatment of MDA-MB-231 cells alone showed a modest
but not significant increase in G1 phase arrest, a modest
d e c r e a s ei nt h eSp h a s ea n dl i t t l ee f f e c to nt h eG 2/M
phase (Figure 8A). However, the combination of PEA3
knockdown and MRK-003 GSI treatment resulted in a
significant increase in the G1 phase compared to control
(P < 0.05) (Figure 8A). In the presence of both PEA3
knockdown and MRK-003 GSI treatment, there was a
significant reduction in the S phase of the cell cycle
compared to control (P < 0.05). Also, both PEA3 knock-
down and MRK-003 GSI treatment resulted in a signifi-
cant reduction in the G2/M phase of the cell cycle
compared to control (P < 0.05) (Figure 8A). These
results indicate that both PEA3 and Notch are critical
for the proliferation of MDA-MB-231 cells.
We then asked whether dual inhibition using both PEA3
knockdown and Notch inhibition affect cell viability,
potentially through increased apoptosis. Independently,
PEA3 knockdown showed no change in apoptosis as mea-
sured by (1) annexin V staining (Figure 8B) or (2) cell via-
bility using trypan blue exclusion (Figure 8C). MRK-003
GSI treatment alone increased apoptosis to 30% (Figure
8B) and decreased cell viability to 60% (Figure 8C). Impor-
tantly, the combination of PEA3 knockdown and MRK-
003 GSI treatment significantly increased apoptosis to
almost 40% as measured by positive staining of annexin V
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Page 12 of 18cells (Figure 8B) and diminished cell viability to 50%
(Figure 8C). These results, taken together with the cell
cycle data, indicate that both PEA3 and Notch activities are
critical for cell proliferation and survival in MDA-MB-231
breast cancer cells.
Dual inhibition of Notch and PEA3 inhibits anchorage-
independent growth
To address whether dual inhibition of PEA3 and Notch
activities affect anchorage-independent growth as an in
vitro measure of tumorigenicity, we performed a colony
formation assay with MDA-MB-231 cells that were
transfected with either scrambled control or PEA3
siRNA and treated with vehicle or MRK-003 GSI inde-
pendently or in combination. We observed a reduction
of almost 55% in the number of colonies when PEA3
was knocked down or 61% when Notch was inhibited
using a GSI in cells compared to vehicle + control
siRNA control (Figures 9A and 9B). Furthermore, the
number of colonies was reduced further to 20% upon
PEA3 knockdown and GSI treatment compared to vehi-
cle + control siRNA (Figures 9A and 9B).
Tumor growth of MDA-MB-231 xenografts is dependent
on PEA3 or Notch activity
The results so far have indicated that dual inhibition of
PEA3 and Notch signaling inhibits both anchorage-depen-
dent and anchorage-independent cell growth in vitro more
effectively than either treatment alone. The results from
the anchorage-independent assay suggest that transient
knockdown of PEA3 using siRNA is sufficient to inhibit
the formation of colonies for up to two weeks. On the
basis of these results, we asked whether transient knock-
down of PEA3 could inhibit tumor formation in vivo and
whether treatment with MRK-003 GSI in combination
could prevent tumor formation. We performed an ortho-
topic MDA-MB-231 tumor xenograft study in athymic
mice. MDA-MB-231 cells were transfected with control or
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Figure 7 Differential regulation of Notch-4 by AP-1 members. (A) MDA-MB-231 cells were transfected with control, PEA3, Fra-1, c-JUN or c-
FOS siRNA for 48 hours as described previously. Real-time PCR was performed to detect Notch-4 and HPRT transcripts. Transcript expression
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Page 13 of 18PEA3 siRNA in vitro (Figure 9D) and then injected into
the mammary fat pads of female athymic mice. The mice
were randomized to injection with vehicle control or
MRK-003 GSI. The results showed that either PEA3
knockdown or GSI treatment significantly reduced tumor
growth by almost similar rates compared to vehicle +
scrambled control siRNA (Figure 9C).
We have shown for the first time, to our knowledge,
that PEA3 is a novel activator of Notch-1 and Notch-4
transcription in different subtypes of breast cancer cells
and could prove to be an important therapeutic target,
possibly upstream of Notch-1 and/or Notch-4 signaling.
Discussion
PEA3 was originally identified as a member of the ETS
family of transcription factors. Since then, it has been
observed that PEA3 is expressed during normal breast
development, is quickly lost upon maturation and yet
reemerges in metastatic breast cancers [33,54,61,66-68].
Similarly, Notch has been implicated in breast cancer,
demonstrating elevated expression and activity in breast
tumors [25,26]. Little is known about the factors that
influence Notch gene expression and why its levels are
elevated in breast cancer. Herein we provide the first evi-
dence of transcriptional regulation of Notch-1 and Notch-
4 by PEA3 in MDA-MB-231 and other breast cancer
subtypes (Figures 1 through 3). We have demonstrated
that Notch-4 gene regulation is dependent on AP-1 fac-
tors such as c-Jun, Fra-1, c-Fos and now PEA3, depend-
ing on cellular context (Figures 5 and 7). Interestingly,
we provide evidence that c-Jun and Fra-1 are transcrip-
tional activators of Notch-4, but that c-FOS could be a
transcriptional repressor of Notch-4 (Figure 7). PEA3 reg-
ulates the Notch-1 promoter, but the additional factors
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Figure 8 Dual inhibition of Notch and PEA3 inhibits cell proliferation and induces apoptosis. MDA-MB-231 cells were transfected with
scrambled or PEA3 siRNA alone or were treated with vehicle (DMSO) or a g-secretase inhibitor (MRK-003 GSI), or a combination thereof, for 48
hours. Cell cycle analysis (A) and annexin V staining (B) were performed by using flow cytometry. (C) Percentages of viable cells were measured
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Page 14 of 18that aid in that regulation are still being investigated.
Further evidence reveals that PEA3 inhibition helps sen-
sitize MDA-MB-231 cells to a GSI, showing promise in
significantly reducing both anchorage-dependent and
anchorage-independent growth as well as increasing
apoptosis in vitro (Figures 8, 9A and 9B). Moreover,
PEA3 expression or Notch activity is required for optimal
growth of MDA-MB-231 tumors in vivo (Figure 9C).
Thus, PEA3 emerges as a potential target, possibly
upstream of Notch activity, for triple-negative cancer and
possibly other breast cancer subtypes where PEA3 and/or
Notch activities are critical for growth. This was evident
in the preclinical model of our MDA-MB-231 xenograft
study (Figure 9C). Either PEA3 knockdown or GSI treat-
ment was adequate to significantly inhibit tumor growth
in vivo. This result could suggest that targeting PEA3, a
transcriptional activator of Notch-1 and Notch-4, hits
multiple targets at once. For example, PEA3 is an
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Figure 9 Inhibition of Notch and PEA3 inhibits anchorage-dependent growth in vitro and tumor growth in vivo. (A) and (B) MDA-MB-
231 cells were transfected with either scrambled or PEA3 siRNAa and treated with vehicle (DMSO) or g-secretase inhibitor (MRK-003 GSI)
independently or in combination for 48 hours. A colony formation assay was performed using methylcellulose, and the colonies were incubated
for 14 days. (A) Colonies were photographed using a standard light microscope (×40 original magnification). The photomicrographs are
representative of three independent experiments. (B) Twelve fields per well were counted, and the means plus or minus standard deviations of
three independent experiments were plotted. Statistical significance was determined by performing analysis of variance for multiple
comparisons. (C) Cells were injected into each of two mammary fat pads of female athymic nude mice which were number-tagged prior to
surgery to monitor each tumor. The mice were randomized to vehicle or MRK-003 GSI, which was fed orally by gavage on a schedule of three
days on, four days off. Tumor areas (length × width) were measured twice per week using vernier calipers for up to 3.5 weeks. The y-axis is
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**Denotes statistical differences between MRK-003 GSI + Controli and vehicle + Controli. (D) MDA-MB-231 cells were transfected with control or
PEA3 siRNAa for 24 hours. Real-time PCR was performed on MDA-MB-231 cells prior to injection to detect PEA3 transcripts.
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Page 15 of 18activator of MMPs [36-39,53], uPAR [55,56], COX-2 [35]
and now Notch-1 and Notch-4. PEA3 expression and
Notch signaling could be critical for tumor formation
and communication with the tumor microenvironment,
which is not possible to recapitulate in vitro using single-
cell suspensions. The severe side effects associated with
GSI treatment, such as gastrointestinal toxicity [69,70],
could possibly be avoided if inhibition of PEA3 is able to
inhibit several growth- and metastasis-promoting signal-
ing pathways.
Notch is a cellular fate determinant and can induce
cell proliferation and/or differentiation, depending on
the cellular environment [71]. PEA3 has been linked to
the invasion, migration and aggressiveness of tumor
cells [33,40,53,54,57,61,67,68,72,73]. The dual or indivi-
dual inhibition of Notch by the GSI, and the inhibition
of PEA3 by siRNA, acts by preventing two vital arms of
cancer progression, namely, growth and possibly inva-
sion, which we are currently investigating in vitro and in
vivo. Emerging nanotechnology can be used as a means
by which to direct siRNA therapies [74], and the advent
of stapled interface peptides [75] that disrupt transcrip-
tion factor complexes transforms the notion of specific
targeting of the PEA3 transcription factor into a poten-
tial reality.
In addition, Harrison et al. [27] implicated Notch-4 in
mammary tumor stem cell survival and self-renewal in a
recent study in which they demonstrated that targeting
Notch-4 specifically was more effective than a targeting
a GSI in inhibiting the Notch pathway. In our studies,
we found that Notch-4 gene transcription was more
sensitive to PEA3 inhibition. Given this fact, the sensi-
tivity that we obtained in our MDA-MD-231 system by
the dual inhibition using a PEA3 siRNA in combination
with MRK-003 GSI reduced viability and increased
apoptosis may be explained by the notion that we may
have targeted not only the proliferation and survival of
bulk cancer cell populations but also possibly the cancer
stem cell population.
Herein we have provided evidence of a novel thera-
peutic strategy to be exploited for the treatment of tri-
ple-negative breast cancer and potentially other breast
cancer subtypes where PEA3 regulates Notch-1 and
Notch-4. Enhanced sensitivity toward current GSIs or
alternative strategies for future clinical trials by inhibi-
tion of PEA3 by nanoparticles, small-molecule inhibitors
or future siRNA approache sm a yi n c r e a s ep a t i e n t
response to treatment and could reduce or eliminate
recurrence if stem cell populations are eliminated. Inhi-
biting PEA3 may also allow for a larger therapeutic win-
dow for GSI treatment, enabling the reduction of
pharmacological doses or possibly eliminating the need
f o rt h eG S Ii fP E A 3i si n d e e du p s t r e a mo fN o t c h
signaling, thus lowering resultant undesirable side effects
such as gastrointestinal toxicity and possibly skin cancer.
Conclusions
Taken together, the results from this study demonstrate
for the first time that Notch-1 and Notch-4 are novel
transcriptional targets of PEA3 in breast cancer cells.
PEA3 emerges as a potential innovative target upstream
from Notch activity for triple-negative cancer and possi-
bly other breast cancer subtypes where PEA3 and/or
Notch activities are critical for growth and aggressive
phenotypes. The significance of targeting of PEA3 and/
or Notch pathways allows a potentially novel therapeutic
strategy for the treatment of breast cancers.
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